Allurion Technologies Faces Delisting Concerns

TL;DR

Allurion might get delisted - big trouble for shareholders.

AI Summary

Allurion Technologies, Inc. filed an 8-K on August 15, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates potential issues with the company's continued listing on the stock exchange, though specific details regarding the rule or standard not met are not provided in this excerpt.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the stock being removed from trading, impacting investors.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• Allurion Technologies, Inc. (company) — Registrant
• August 12, 2024 (date) — Earliest event reported
• August 15, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share ALUR The New York Stock E
• $8.10 — mon stock, each at an exercise price of $8.10 per share of common stock ALUR WS T
• $1.00 — he Company's common stock was less than $1.00 per share over the consecutive 30 tradi

Filing Documents

• alur-20240812.htm (8-K) — 51KB
• alur-ex99_1.htm (EX-99.1) — 19KB
• 0000950170-24-097653.txt ( ) — 226KB
• alur-20240812.xsd (EX-101.SCH) — 47KB
• alur-20240812_htm.xml (XML) — 7KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 12, 2024, Allurion Technologies, Inc. (the "Company") received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") that it is not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE's Listed Company Manual ("Section 802.01C") because the average closing price of the Company's common stock was less than $1.00 per share over the consecutive 30 trading-day period ended August 8, 2024. The Notice does not result in the immediate delisting of the Company's common stock from the NYSE. The Company can regain compliance at any time within a six-month cure period following its receipt of the Notice if, on the last trading day of any calendar month during such cure period, the Company has both: (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of the applicable calendar month. The Company intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE's continued listing standards, including, but not limited to, a reverse stock split, subject to stockholder approval. Section 802.01C provides for an extension to the six-month cure period if the action required to cure the price condition requires stockholder approval, in which case, the action needs to be approved by no later than the Company's next annual stockholder's meeting and implemented promptly thereafter. The Notice has no immediate impact on the listing of the Company's common stock, which will continue to be listed and traded on the NYSE during such cure period, subject to the Company's compliance with other NYSE continued listing standards. The Company's common stock will continue to trade on the NYSE under the symbol "ALUR" with the designation of ".BC" to indicate th

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. As required by Section 802.01C, the Company issued a press release on August 15, 2024, announcing that it had received the notice of noncompliance with the NYSE's continued listing standards. A copy of the press release is being furnished herewith as Exhibit 99.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release of Allurion Technologies, Inc., dated August 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALLURION TECHNOLOGIES, INC. Date: August 15, 2024 By: /s/ Brendan Gibbons Name: Title: Brendan Gibbons Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR